The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash.
Thomas Goehler
No relevant relationships to disclose
Marcus A. Woerns
No relevant relationships to disclose
Holger Frithjof Hebart
No relevant relationships to disclose
Michael Heike
No relevant relationships to disclose
Michael Neise
No relevant relationships to disclose
Jochen Rudi
No relevant relationships to disclose
Thomas Geer
No relevant relationships to disclose
Gerrit Dingeldein
No relevant relationships to disclose
Claudia Lang
No relevant relationships to disclose
Peter Ehscheidt
No relevant relationships to disclose
Thomas Flohr
No relevant relationships to disclose
Klaus Maria Josten
No relevant relationships to disclose
Meinolf Karthaus
No relevant relationships to disclose
Alexander H. Schmittel
No relevant relationships to disclose
Jan Wierecky
No relevant relationships to disclose
Peter Robert Galle
No relevant relationships to disclose
Carmen Dhensaw
No relevant relationships to disclose
Markus Hermann Moehler
Consultant or Advisory Role - Merck
Honoraria - Merck
Carl Christoph Schimanski
Honoraria - Merck Serono
Research Funding - Merck Serono